Test Your Skills in Managing These Patients
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Aboud M, Orkin C, Podzamczer D, et al. Lancet HIV. 2019;6(9):e576-e587.
Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps.
Boyd MA, Boffito M, Castagna A, Estrada V. HIV Med. 2019;20(suppl 1):3-11.
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
Daar ES, DeJesus E, Ruane P, et al. Lancet HIV. 2018;5(7):e347-e356.
HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable.
Eisinger RW, Dieffenbach CW, Fauci AS. JAMA. 2019;321(5):451-452.
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ, Orkin C, Cunningham D, et al. Antiviral Res. 2019;170:104543.
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
Gallant JE, Daar ES, Raffi F, et al. Lancet HIV. 2016;3(4):e158-e165.
Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years: final 96‑week results of the NEAT022 study.
Gatell JM, Assoumou L, Moyle G, et al. Clin Infect Dis. 2019;68(4):597-606.
Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study.
Getahun D, Nash R, Flanders WD, et al. Ann Intern Med. 2018;169(4):205-213.
Sexualized drug use (chemsex) is associated with high-risk sexual behaviors and sexually transmitted infections in HIV-positive men who have sex with men: data from the U-SEX GESIDA 9416 study.
González-Baeza A, Dolengevich-Segal H, Pérez-Valero I, et al; the U-SEX GESIDA 9416 Study. AIDS Patient Care STDS. 2018;32(3):112-118.
Human immunodeficiency virus and trans women: a literature review.
Jaspal R, Kennedy L, Tariq S. Transgend Health. 2018;3(1):239-250.
Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT Trial.
Johnson M, Kumar P, Molina JM, et al; for the DRIVE-SHIFT Study Group. J Acquir Immune Defic Syndr. 2019;81(4):463-472.
Cross-sectional analysis of chemsex drug use and gonorrhoea diagnosis among men who have sex with men in the UK.
Kohli M, Hickson F, Free C, Reid D, Weatherburn P. Sex Health. 2019;16(5):464-472.
HIV among black men who have sex with men (MSM) in the United States: a review of the literature.
Maulsby C, Millett G, Lindsey K, et al. AIDS Behav. 2014;18(1):10-25.
Factors associated with antiretroviral therapy adherence among transgender women receiving HIV medical care in the United States.
Mizuno Y, Beer L, Huang P, Frazier EL. LGBT Health. 2017;4(3):181-187.
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM, Ward D, Brar I, et al. Lancet HIV. 2018;5(7):e357-e365.
The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting.
Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. J Acquir Immune Defic Syndr. 2017;74(1):44-51.
Global epidemiology of HIV infection and related syndemics affecting transgender people.
Poteat T, Scheim A, Xavier J, Reisner S, Baral S. J Acquir Immune Defic Syndr. 2016;72(suppl 3):S210-219.
Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppression: randomized, open-label, noninferiority DUAL-GESIDA 8014-RIS-EST45 trial.
Pulido F, Ribera E, Lagarde M, et al; for the DUAL-GESIDA-8014-RIS-EST45 Study Group. Clin Infect Dis. 2017;65(12):2112-2118.
Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices.
Radix A, Sevelius J, Deutsch MB. J Int AIDS Soc. 2016;19(3 suppl 2):20810.
Switching antiretroviral regimes for the treatment of HIV: safety implications.
Utrillo L, Vidal F, Puig T, Domingo P. Expert Opin Drug Saf. 2016;15(10):1349-1360.
Clinical Practice Guidelines
Recommendations for evaluation and management of bone disease in HIV.
Brown TT, Hoy J, Borderi M, et al. Clin Infect Dis. 2015;60(8):1242-1251.
Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People.
Coleman E, Bockting W, Botzer M, et al. 7th ed. East Dundee, Illinois: World Professional Association for Transgender Health.
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel.
Saag MS, Benson CA, Gandhi RT, et al. JAMA. 2018;320(4):379-396.
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV.
US Department of Health and Human Services
Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy.
World Health Organization
Patient and Caregiver Resources
AIDSMap Resources
NAM Publications
Resources for persons living with HIV
Centers for Disease Control and Prevention
HIV Resources
National Institutes of Health
Fenway Health
UCSF Transgender Care
University of California San Francisco
HIV Waiting Room: Newly diagnosed transgender woman
Test Your Skills in Managing These Patients
| Faculty: | Bruce Hinton PA-C, AAHIVMS; Carole Pindaro, APRN |
| Release: | 10/31/2019 |
| Expiration: | 03/18/2021 |
HIV Waiting Room: Newly diagnosed young MSM with a history of recreational drug use
Test Your Skills in Managing These Patients
| Faculty: | Christian B. Ramers, MD, MPH; Richard A. Elion, MD, MA |
| Release: | 11/15/2019 |
| Expiration: | 03/18/2021 |
HIV Waiting Room: Well-informed, HIV treatment-experienced patient looking for updates on switching regimens and emerging approaches to treatment
Test Your Skills in Managing These Patients
| Faculty: | Carlos Del Rio, MD; Richard A. Elion, MD, MA |
| Release: | 12/18/2019 |
| Expiration: | 03/18/2021 |
